Balboa Wealth Partners Purchases Shares of 492 Axon Enterprise, Inc. (NASDAQ:AXON)

Balboa Wealth Partners acquired a new position in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 492 shares of the biotechnology company's stock, valued at approximately $292,000.

Several other hedge funds have also recently made changes to their positions in the business. Geode Capital Management LLC raised its position in shares of Axon Enterprise by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company's stock worth $710,103,000 after acquiring an additional 35,320 shares in the last quarter. Westfield Capital Management Co. LP increased its position in Axon Enterprise by 12.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company's stock valued at $469,661,000 after buying an additional 127,769 shares in the last quarter. Champlain Investment Partners LLC increased its position in Axon Enterprise by 13.9% in the 3rd quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company's stock valued at $272,695,000 after buying an additional 83,265 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Axon Enterprise by 1.6% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company's stock valued at $224,281,000 after buying an additional 9,090 shares in the last quarter. Finally, Groupama Asset Managment bought a new stake in Axon Enterprise in the 3rd quarter valued at about $200,000. 79.08% of the stock is owned by institutional investors.

Remove Ads

Insider Transactions at Axon Enterprise

In related news, insider Jeffrey C. Kunins sold 1,035 shares of the stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $624.47, for a total value of $646,326.45. Following the sale, the insider now owns 124,243 shares in the company, valued at approximately $77,586,026.21. This trade represents a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total value of $271,831.50. Following the completion of the sale, the director now owns 6,929 shares in the company, valued at $4,185,601.03. This trade represents a 6.10 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company's stock.

Axon Enterprise Stock Performance

NASDAQ AXON traded down $14.83 on Tuesday, hitting $539.99. 558,270 shares of the stock traded hands, compared to its average volume of 857,660. The business's fifty day moving average is $593.10 and its two-hundred day moving average is $538.04. Axon Enterprise, Inc. has a 12 month low of $273.52 and a 12 month high of $715.99. The firm has a market capitalization of $41.38 billion, a price-to-earnings ratio of 139.53, a PEG ratio of 5.17 and a beta of 1.12. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Craig Hallum lowered Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. Northcoast Research lowered Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. Morgan Stanley raised Axon Enterprise from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $500.00 to $700.00 in a research report on Tuesday, December 3rd. JMP Securities reaffirmed an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Finally, TD Cowen assumed coverage on Axon Enterprise in a research report on Wednesday, January 8th. They issued a "buy" rating and a $700.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $604.67.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.